home > news > detailed info

PCI Pharma Services Announces Appointment of Angi Calkins as Chief Human Resources Officer

PCI Pharma Services

Calkins to lead global human resource team for PCI during time of considerable expansion

Philadelphia, PA – January 28, 2019. Leading biopharmaceutical services provider PCI Pharma Services (PCI) is pleased to announce the appointment of Angi Calkins as Senior Vice President and Chief Human Resources Officer. Angi joins PCI as the company experiences considerable growth and global expansion, currently with more than 3,500 associates, spanning eight locations comprised of 20 facilities across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.

Angi brings significant experience to PCI gained during an impressive career in human resources leadership across multiple and diverse industries including pharmaceutical and life sciences, retail, consumer goods, global HR outsourcing and financial services. Angi joins PCI having served in senior leadership roles at Regeneron Pharmaceuticals, a leading biotechnology company that doubled in size, was recognized each year by Forbes as one of the 100 Greatest Places to Work, and was ranked the industry’s number one Biopharma Employer by Science Magazine during three of her four years in post

Commenting on Angi’s appointment, PCI Chief Executive Officer Salim Haffar noted: “PCI is at a transformative time. We have a celebrated history of partnering with leading pharmaceutical and biotech companies to support bringing their life-saving medicines to patients around the world. Building on those trusted relationships, over the past 12 months we have changed the complexion of the company with acquisitions in key geographies including Dublin, Ireland; Melbourne, Australia; and San Diego, California, bringing new capabilities and greater access to global emerging markets.

“Our company is rich in cutting-edge science and technology, rooted in a dedication to outstanding service and quality. This is achieved through a talented and dedicated workforce. I am very pleased to have Angi join at such an exciting time and am eager to see her insights and leadership help shape the future of the company.”

“I am delighted for this opportunity,” stated Angi. “Across my career I have had opportunities to learn about and excel in both in-house and outsource partnership organizations, and PCI is a uniquely inspiring fit for my background and my passion for people and talent at the heart of great business. I was attracted to PCI by virtue of its outstanding reputation in the industry, its focus on continued investment and global growth, and certainly its singular commitment to delivering outstanding service and industry-leading quality for its clients, ultimately playing a critical role in the lives of our clients’ patients around the world. PCI has demonstrated through its investments and focus on developing a growing global workforce that it is committed to meeting the unique and ever-evolving needs of its clients, both in the short- and the long-term. I am excited to be part of that growth and expansion.”

In addition to key acquisitions in Melbourne, Australia and San Diego, California, PCI recently announced ground-breaking on site expansion at its Rockford, Illinois facility. This complements recently executed site expansions at its European clinical Center of Excellence in Bridgend and its manufacturing Center of Excellence in Tredegar, UK as well as investments at sites in Dublin, Ireland; Hay-on-Wye, UK; and Philadelphia, PA.

For more information, please visit

About PCI Pharma Services
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives. For more information, please visit or follow us on Twitter at @PCI_Social.

Tom Gosschalk / Carrie Lowe at BECG /
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
Print this page
Send to a friend
News and Press Releases

Aptar Pharma Co Organizer and Diamond Sponsor of RDD Europe 2019 Conference in Estoril Portugal

Crystal Lake, Illinois, March 21, 2019 Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its coorganization and diamond sponsorship of the Respiratory Drug Delivery (RDD®) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible


The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement